GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » E10

SLNO (Soleno Therapeutics) E10 : $-48.29 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Soleno Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.830. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-48.29 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-12), Soleno Therapeutics's current stock price is $47.17. Soleno Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-48.29. Soleno Therapeutics's Shiller PE Ratio of today is .


Soleno Therapeutics E10 Historical Data

The historical data trend for Soleno Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics E10 Chart

Soleno Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -97.75 -75.30

Soleno Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.41 -75.30 -70.83 -51.60 -48.29

Competitive Comparison of Soleno Therapeutics's E10

For the Biotechnology subindustry, Soleno Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soleno Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Soleno Therapeutics's Shiller PE Ratio falls into.



Soleno Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Soleno Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.83/133.0289*133.0289
=-1.830

Current CPI (Sep. 2024) = 133.0289.

Soleno Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -79.981 99.070 -107.397
201503 -125.250 99.621 -167.252
201506 18.750 100.684 24.773
201509 -24.750 100.392 -32.796
201512 -6.750 99.792 -8.998
201603 -16.500 100.470 -21.847
201606 -17.250 101.688 -22.567
201609 -13.050 101.861 -17.043
201612 -29.850 101.863 -38.983
201703 -8.550 102.862 -11.057
201706 -6.300 103.349 -8.109
201709 -5.850 104.136 -7.473
201712 -6.000 104.011 -7.674
201803 -2.850 105.290 -3.601
201806 -5.250 106.317 -6.569
201809 -1.950 106.507 -2.436
201812 0.150 105.998 0.188
201903 -3.300 107.251 -4.093
201906 -4.650 108.070 -5.724
201909 -2.850 108.329 -3.500
201912 -5.400 108.420 -6.626
202003 -1.950 108.902 -2.382
202006 -2.400 108.767 -2.935
202009 -1.650 109.815 -1.999
202012 -0.600 109.897 -0.726
202103 -1.650 111.754 -1.964
202106 -2.100 114.631 -2.437
202109 -1.530 115.734 -1.759
202112 -0.530 117.630 -0.599
202203 -1.070 121.301 -1.173
202206 -0.720 125.017 -0.766
202209 -0.650 125.227 -0.690
202212 -0.580 125.222 -0.616
202303 -0.880 127.348 -0.919
202306 -0.810 128.729 -0.837
202309 -0.950 129.860 -0.973
202312 -0.357 129.419 -0.367
202403 -0.590 131.776 -0.596
202406 -0.570 132.554 -0.572
202409 -1.830 133.029 -1.830

Add all the adjusted EPS together and divide 10 will get our e10.


Soleno Therapeutics  (NAS:SLNO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Soleno Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics Business Description

Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Executives
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505